Additional Effect of Hyperparathyroidism on Inflammatory Status and rHuEPO Requirements in Hemodialysis Patients

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2807-2812

  Tutal, E ^a   Sezer, S ^a   Afsar, B ^a   Arat, Z ^a   Ozdemir, F N ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; PREALBUMIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC INFLAMMATION; DRUG SAFETY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; IRON THERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

ADULT; AGED; ALBUMINURIA; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; HYPERPARATHYROIDISM; INFLAMMATION; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33750935273     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.104     Document Type: Article

References (28)

1. Ifudu O. Care of patients undergoing hemodialysis. N Engl J Med 339 (1998) 1054
2. Eschbach J.W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35 (1989) 134
3. Drüeke T.B. Primary and secondary uraemic hyperpareathyroidism: from initial clinical observations to recent findings. Nephrol Dial Transplant 13 (1998) 1384
4. Eschbach J.W., Haley N.R., Egrie J.C., et al. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 42 (1992) 407
5. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30 4 Suppl 3 (1997) S192
6. Gallieni M., Corsi C., and Brancaccio D. Hyperparathyroidism and anemia in renal failure. Am J Nephrol 20 (2000) 89
7. Ifudu O. Patient characteristics determining rHuEPO dose requirements. Nephrol Dial Transplant 17 Suppl 5 (2002) 38
8. Drüeke T.B. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 Suppl 7 (2001) 25
9. Van Wyck D.B., Stivelman J.C., Ruiz J., et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35 (1989) 712
10. Fako J.M., Guy J.T., Smith R.E., et al. Primary hyperparathyroidism and anemia. Arch Intern Med 136 (1976) 887
11. Boxer M., Ellman L., Geller R., et al. Anemia in primary hyperparathyroidism. Arch Intern Med 137 (1977) 588
12. Depner T.A. Prescribing hemodialysis: a guide to urea modeling (1991), Kluwer, Boston 65
13. Working Party for European Best Practice Guidelines for the Management of Anemia in Patients With Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14 Suppl 5 (1999) S1
14. Barany P., Divino Filho J.C., and Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29 (1997) 565
15. Horl W.H., Jacobs C., Macdougall I.C., et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 15 Suppl 4 (2000) 43
16. Sezer S., Kulah E., Ozdemir F.N., et al. Clinical consequences of intermittent elevation of C-reactive protein levels in hemodialysis patients. Transplant Proc 36 (2004) 38
17. Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol Dial Transplant 10 Suppl 6 (1995) 27
18. Kayse G.A. Inflammation: cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol 24 (2004) 431
19. Tonelli M., Blake P.G., and Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 47 (2001) 82
20. Drueke T.B. R-HuEPO hyporesponsiveness-who and why?. Nephrol Dial Transplant 10 Suppl 2 (1995) 62
21. Lowik C.W., van der Pluim G., Bloys H., et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162 (1989) 1546
22. Li N.H., Ouchi Y., Okamoto Y., et al. Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells. Biochem Biophys Res Commun 179 (1991) 236
23. Greenfield E.M., Shaw S.M., Gomik S.A., et al. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 96 (1995) 1238
24. Grey A., Mitnick M.A., Shapses S., et al. Circulating levels of interleukin-6 and tumor necrosis factor-a are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab 81 (1996) 3450
25. McCarty M.F. Secondary hyperparathyroidism promotes the acute phase response - a rationale for supplemental vitamin D in prevention of vascular events in the elderly. Medical Hypotheses 64 (2005) 1022
26. Van den Berghe G., Van Roosbroeck D., Vanhove P., et al. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 88 (2003) 4623
27. Goicoechea M., Gomez-Campdera F., Polo J.R., et al. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy. Clin Nephrol 45 (1996) 420
28. Albitar S., Genin R., Fen-Chong M., et al. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 12 (1997) 514